The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
TGTD,
You are a silly billy!
Wonder if AZ have registered labs in which they can validate what the hell they wish in the blink of an eye!
You just sit quietly in the corner. Everything will be alright :-)
Thanks C11,
Just to add that both may prove to have further utility and each will plough it's own furrow so to speak. It is important to remember the development opportunities that may arise from these types of platform. There-in lays the real value me thinks. But first lets get iSCIB1+ validated!
Looks like Vulpes were holding shares in Chronus as a private company which have now translated to an Evgen holding. There may or may not have been some additional buying.
Yes and Scancell
Agree Rick and thanks Bermuda for the link. Not seeing any real gains today is very odd but the market is clapped out so I guess brilliant news is just wasted on AIM? I am watching out for another hot RNS that might kick start a rise before results.
Started a new thread as Ripley seems to be going for a deramping thread length record. Maybe the kind that somehow ends up weirdly showing organically on google? Yep, delusional...
I am sure he thinks he is providing balance so we don't all get carried away when the share price balloons with news. It is one thing however holding a child's 10 pence balloon at the fair, quite another when it turns out to be a hot air balloon. An easy mistake to make if you are blinded by negativity! Don't fancy your chances of holding this down with ribbon string news starts flowing Rippa. My advice, just let it go, stand back, and admire it.
Chin up sausage
Any news for anybody re liquid biopsy is good news for Angle; Angle don't have to, "win." They don't have to be crowned, "world champions." Just taking part is fine, remaining alive, relevant and gain a foothold with increasing income momentum towards break even.
This is not do or die in that sense.
A lot of negative focus on this thread. Makes one think…
If people identified a negative share they would simply not invest or sell and walk away. NOT talk about it minute after minute, hour after hour.
Very peculiar behaviour.
I therefore have to ask, what is in it for them?
Would make a fascinating psychological study imo.
Bantham,
You say that people get sucked in by the rampers and get spiked and end up selling low. You add that it happens multiple times... So what you are saying is that the price goes up and down repeatedly. Well brace yourself as I have too inform you that this is quite normal share price behavior! I would also add, you simply don't know when others buy or sell.
I see Avidimab as a pre-clinical asset.
As we know it is currently involved in SCOPE. If we assume that iSCIB1+ takes over from SCIB1 and provides above the assumed 70% ORR and a durable response, we must accept that Avidimabs role is not stand alone in that instance. It will have become part of the package iSCIB1+, which imo would be successfully demonstrated as THE stand alone asset. So Avidimab plus something else makes a stand alone asset = Avidimab makes a hybrid but is not the actual asset.
So my question is, despite having a significant role in say a SEAGEN or Scancell trial, why on earth would either company water down the subject of there own successful clinical asset (SEA-CD40 or iSCIB1+) by saying that it was due in part to Avidimab? Remember the objective of the trial being to prove the stand alone asset, not the delivery method etc etc.It is wholly more likely in my view that both SEAGEN and Scancell would be encouraged but still be unable to prove the exact role Avidimab plays without a robust trial of its own.
Finally, it may well become important for the regulatory bodies to understand the role Avidimab plays... This is because if it is not clearly defined, it could be used to boost poor drug candidates results. If for instance FDA were able to understand definitively what it does, then it would make distinguishing trial results clearer.
Conclusion: Avidimab needs its own trials. It could prove itself to be a successful mab in its own right; a successful asset in its own right. Maybe more likely in combination? This would mean it could be worth billions. But until then, the only way forward is if there are brave maverick entrepreneurial types willing to take it on. Or the more sensible types that will give it a six month assessment and maybe a milestone deal?
Anyway, these are not my definitive thoughts, just spit balling so feel free to tell me I am wrong!